These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8540350)

  • 21. Three-dimensional solution structure of the HIV-1 protease complexed with DMP323, a novel cyclic urea-type inhibitor, determined by nuclear magnetic resonance spectroscopy.
    Yamazaki T; Hinck AP; Wang YX; Nicholson LK; Torchia DA; Wingfield P; Stahl SJ; Kaufman JD; Chang CH; Domaille PJ; Lam PY
    Protein Sci; 1996 Mar; 5(3):495-506. PubMed ID: 8868486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
    Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
    Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of HIV-1 protease mutants: random, directed, selected.
    Swanstrom R
    Curr Opin Biotechnol; 1994 Aug; 5(4):409-13. PubMed ID: 7765174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases.
    Tang J; Hartsuck JA
    FEBS Lett; 1995 Jun; 367(2):112-6. PubMed ID: 7796905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
    Fehér A; Weber IT; Bagossi P; Boross P; Mahalingam B; Louis JM; Copeland TD; Torshin IY; Harrison RW; Tözsér J
    Eur J Biochem; 2002 Aug; 269(16):4114-20. PubMed ID: 12180988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
    Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
    J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV protease mutations leading to reduced inhibitor susceptibility.
    Korant B; Lu Z; Strack P; Rizzo C
    Adv Exp Med Biol; 1996; 389():241-5. PubMed ID: 8861017
    [No Abstract]   [Full Text] [Related]  

  • 31. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease.
    Mahalingam B; Louis JM; Reed CC; Adomat JM; Krouse J; Wang YF; Harrison RW; Weber IT
    Eur J Biochem; 1999 Jul; 263(1):238-45. PubMed ID: 10429209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A rapid screening method for biological activity of human immunodeficiency virus proteinase inhibitors by using a recombinant DNA-derived bacterial system.
    Sedlácek J; Fábry M; Horejsí M; Brynda J; Luftig RB; Majer P
    Anal Biochem; 1993 Dec; 215(2):306-9. PubMed ID: 8122796
    [No Abstract]   [Full Text] [Related]  

  • 33. A folding inhibitor of the HIV-1 protease.
    Broglia RA; Provasi D; Vasile F; Ottolina G; Longhi R; Tiana G
    Proteins; 2006 Mar; 62(4):928-33. PubMed ID: 16385559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction of mutant forms of the HIV-1 protease with substrate and inhibitors.
    Darke PL; Kohl NE; Hanobik MG; Leu CT; Vacca JP; Guare JP; Heimbach JC; Dixon RA
    Adv Exp Med Biol; 1991; 306():483-7. PubMed ID: 1812746
    [No Abstract]   [Full Text] [Related]  

  • 35. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
    Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
    J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
    Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
    J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.
    Otto MJ; Garber S; Winslow DL; Reid CD; Aldrich P; Jadhav PK; Patterson CE; Hodge CN; Cheng YS
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7543-7. PubMed ID: 8356053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.
    Moutouh L; Corbeil J; Richman DD
    Proc Natl Acad Sci U S A; 1996 Jun; 93(12):6106-11. PubMed ID: 8650227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.
    Menzo S; Monachetti A; Balotta C; Corvasce S; Rusconi S; Paolucci S; Baldanti F; Bagnarelli P; Clementi M
    AIDS; 2003 Mar; 17(5):663-71. PubMed ID: 12646788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
    Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.